Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19

Next Previous
Search
Trial Profile

A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abivertinib (Primary)
  • Indications COVID-19 pneumonia; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Sponsors Sorrento Therapeutics

    • Most Recent Events

    • 27 Oct 2021 Status changed from active, no longer recruiting to completed, according to a Sorrento Therapeutics media release.
    • 27 Oct 2021 Preliminary results presented in a Sorrento Therapeutics media release.
    • 22 Jun 2021 According to a Sorrento Therapeutics media release, last patient randomized on 7 Apr 2021 in this trial with topline data expected in 3Q2021, If positive, the results of the two parallel and independently run clinical trials (NCT04440007 and NCT04528667) should provide valuable insights into the ability of Abivertinib to help patients with pulmonary distress associated with cytokine storm induced by COVID-19.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top